Evidence map›Paper›PMID 41957847›Full record

ArticleStem cell research & therapy2026

Generation of biologically responsive colon-like intestinal tissue patches from human induced pluripotent stem cells using a rapid co-differentiation platform.

William Dalleywater, Alexander V Predeus, Batuhan Cakir, Pavel Mazin, Jayakumar Vadakekolathu, Sergio Rutella, Marian L Meakin, Alison A Ritchie, Shamir Montazid, Sara Cuevas Ocaña and 15 more

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

William DalleywaterUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK. william.dalleywater@nottingham.ac.uk.
Alexander V Predeus *Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Batuhan Cakir *Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Pavel Mazin *Wellcome Sanger Institute, Hinxton, Cambridge, UK.
Jayakumar Vadakekolathu *John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK.
Sergio Rutella *John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK.
Marian L MeakinUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Alison A RitchieUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Shamir MontazidNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, Oxford, UK.
Sara Cuevas OcañaUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Nadine HolmesSchool of Life Sciences, University of Nottingham, Nottingham, UK.
Victoria WrightSchool of Life Sciences, University of Nottingham, Nottingham, UK.
Fei SangSchool of Life Sciences, University of Nottingham, Nottingham, UK.
Silvia SantoniUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Adam BillsUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Declan SculthorpeUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Rasa ElmentaiteWellcome Sanger Institute, Hinxton, Cambridge, UK.
Sarah A TeichmannWellcome Sanger Institute, Hinxton, Cambridge, UK.
Shazia IrshadNuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, Oxford, UK.
Ian TomlinsonDepartment of Oncology, University of Oxford, Oxford, UK.
Andrew SilverCentre for Genomics and Child Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Ricky D WildmanFaculty of Engineering, University of Nottingham, Nottingham, UK.
Nicholas R F HannanUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK. nick.hannan@nottingham.ac.uk.
Felicity R A J RoseSchool of Pharmacy, Biodiscovery Institute, University of Nottingham, Nottingham, UK. felicity.rose@nottingham.ac.uk.
Mohammad IlyasUnit of Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK. mohammad.ilyas@nottingham.ac.uk.

Funding

Medical Research Council MR/R017336/1Medical Research Council MR/S009930/1National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/X002101/1Pathological Society of Great Britain and Ireland CLSG 1021Pathological Society of Great Britain and Ireland TSGS 1019
6 · The paper itself

Abstract

The intestinal mucosa is a complex functional layer which is formed from a diverse range of cell types that include epithelial cells (within crypts and villi) and an array of mesenchymal cells. Many intestinal diseases involve loss of the surface mucosa which can be difficult to restore, and which delays healing and return to normal function. We reason that development of a transplantable intestinal mucosal tissue graft may be a potential therapeutic strategy to aid healing. To be clinically useful, such a tissue graft would need to be capable of rapid production, avoid the risk of host rejection and be demonstrably safe. To create a potential intestinal graft, we developed a novel early-stage human induced pluripotent stem cell (hiPSC) co-differentiation platform capable of generating multiple intestinal cell lineages (epithelial, mesenchymal and endothelial) in 8 days. This protocol is simple to implement, serum-free and greatly reduces the use of animal products. We confirmed the identity of cells by demonstrating that these cells had RNA and protein expression profiles typical of intestinal cell lineages. In particular, we used bulk and single-cell RNA sequencing to characterise global cellular transcriptional profiles robustly and showed that the cells have intestinal identity with early polarisation towards colonic differentiation. The results were replicated across multiple hiPSC lines and in an independent centre. We further cultured the derived cells on collagen hydrogels to form colon-like intestinal patches (CL-IPs). When transplanted into mouse subcutis, CL-IPs formed into colon-like tissue structures, including crypts, stromal and muscle layers. They also developed human-origin vasculature which underwent anastomosis with the murine vasculature to transport murine blood into the graft. Teratoma assays and molecular analyses showed no evidence of residual pluripotency. While at an early stage, this platform shows great potential for further development as a potential source for novel intestinal mucosal regeneration therapy. In addition, the platform is physiologically relevant and thus shows promise as the basis for a new generation of in vitro models of intestinal pathobiology.

Indexed as

Cell DifferentiationColonInduced Pluripotent Stem CellsIntestinal MucosaAnimalsCell LineageHumansMiceCo-differentiationColonInduced pluripotent stem cellsIntestineTissue engineering

Identifiers

PMID41957847
PMCPMC13173943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.